The United Kingdom and the United States have established a key trade agreement that will ensure zero tariffs on UK medicine products going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to raise funding on medicines through the NHS. This pledge guarantees that import taxes on these vital exports will be held at nothing for a period of 36 months.
This agreement comes after previous statements to dramatically increase import taxes on branded drug products, with increases mentioned as high as double the cost.
"This agreement with the Britain bolsters the worldwide climate for innovative medicines and establishes much-needed equity to American-British pharmaceutical trade," a statement declared.
Trade Importance
Pharmaceuticals represent one of the UK's largest goods shipped to the America, which is by far the primary destination for leading UK drugmakers.
Trade data indicate that in the year leading up to September, the UK sold medicines totaling over eleven billion pounds to the US. This amount accounted for 17.4% of all goods exports in that span.
"This agreement safeguards jobs, increases investment and paves the way for the UK to become a international leader for medical research," the Business and Trade Secretary remarked.
Key UK Commitments
The deal involves several notable commitments from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a target to increase overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to control costs will be restricted at fifteen percent. Previously, rebates topped 20%.
Industry Background
This agreement takes place against a ongoing dispute between the pharmaceutical industry and the ministers over spending levels and regulatory access.
These tensions were intensified by assertions that US customers were paying several times more for the equivalent treatments than patients in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been delayed or scrapped, while major investments have been directed toward US facilities.
A senior figure publicly accepted that the NHS must spend more on treatments, noting that its budget allocation on drugs had declined as a proportion of its total funding over the last ten years.
